Abstract
Candidiasis is an infection caused by the Candida species. Invasive candidiasis is a severe and invasive form of infection, with manifestations that can be found in the blood (candidemia) or other organs (disseminated candidiasis). Early antifungal therapy is important for the management of invasive candidiasis and may reduce mortality. To date, the diagnosis of invasive candidiasis has been difficult and the criteria for empiric antifungal therapy have not been clearly defined. Risk assessment was developed as a clinical predictor to identify patients at risk of invasive candidiasis, provide appropriate and timely antifungal therapy, and avoid wasteful use of antifungal drugs. Risk assessments can be established based on the epidemiology of each health service or currently published risk assessments.
Reference29 articles.
1. Rinawati W, Kumalawati J, Bardosono S, Immanuel S, Sukartini N, Indrasari ND. Invasive candidiasis among high prevalence neurological patients. Journal of Infection in Developing Countries. 2022;(5):871-880. DOI: 10.3855/jidc.15231
2. Hermsen ED, Njoku J, Pfeifer R, Schooneveld TV. The Nebraska Medical Center Guidelines for Management of Invasive Candidiasis. Nebraska: The Nebraska Medical Center Clarkson and University Hospital; 2010
3. Groth CM, Dodds-Ashley ES. Fungal infections in the ICU. In: Infection Critical Care. Lenexa: CCSAP; 2016. Available from:
4. Hankovszky P, Társy D, Öveges N, Molnár Z. Invasive infections in the ICU: Diagnosis and therapy. The Journal of Critical Care Medicine. 2015;(4):129-139. DOI: 10.1515/jccm-2015-0025
5. Kett DH, Azoulay E, Echeverria PM, Vincent JL. bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. Critical Care Medicine. 2011;:665-670. DOI: 10.1097/CCM.0b013e318206c1ca